第一个针对CD19的第三代CAR-T细胞应用,用于治疗具有底层边缘区域淋巴瘤的全身IgM AL氨基粉症

相关实验视频

Updated: Jul 13, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K

Felix Korell1, Stefan Schönland1, Anita Schmitt1

  • 1Department of Hematology & Oncology, Amyloidosis Center, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.

Biomarker research
|October 14, 2023
PubMed
概括

针对CD19的CAR T细胞疗法为患有潜在B细胞淋巴瘤的患者提供了一种新的轻链氨基粉症 (AL) 的有效治疗方法. 这种方法表明了具有可控毒性的深度血液学反应.

关键词:
氨基粉症是什么?在CAR T细胞疗法中.免费提供轻链.的IgM IgM 的情况.边缘区域淋巴瘤 边缘区域淋巴瘤

更多相关视频

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.8K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

590

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
539